Disability Solutions - New York, NY
posted 2 months ago
The SMid-Cap Biotechnology Equity Research team is focused on analyzing companies within three primary disease areas: oncology, central nervous system disorders, and rare diseases. The lead analyst of this team is recognized as one of the top three ranked analysts in the Institutional Investor vote for the smid biotech category. In 2021, the team was actively involved in several priced IPOs and additional transactions, and they are currently evaluating more opportunities. This dynamic environment requires a candidate who is intellectually curious and eager to learn, as they will be integral to the research process alongside the Senior Analyst and Associates. The role encompasses a variety of responsibilities, including writing comprehensive industry and company reports, initiating company launches, and developing surveys and conducting interviews with doctors to gain insights into market dynamics and future projections. The candidate will also be responsible for building financial models to quantitatively assess company valuations and demonstrating a solid understanding of industry knowledge, including regulatory and pricing aspects from early-stage studies to market approval. Building relationships and facilitating information flow with contacts at covered companies is essential, as is the ability to monitor news flow and highlight stock-impacting updates, especially when the Senior Analyst is traveling. Regular interaction with sales, trading, and external clients is expected, and if the team's performance is strong, the candidate may eventually take on coverage of individual names over time.